152 related articles for article (PubMed ID: 35478053)
1. Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model.
Yuan Y; Li D; Hu X; Li Y; Yi W; Li P; Zhao Y; Li Z; Yu A; Jian C; Yu A
Med Oncol; 2022 Apr; 39(5):87. PubMed ID: 35478053
[TBL] [Abstract][Full Text] [Related]
2. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
3. The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction.
He B; Dai L; Zhang X; Chen D; Wu J; Feng X; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
Int J Biol Sci; 2018; 14(13):1845-1858. PubMed ID: 30443188
[TBL] [Abstract][Full Text] [Related]
4. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Zhao B; He T
Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
[TBL] [Abstract][Full Text] [Related]
5. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
Yang Q; Zhang S; Kang M; Dong R; Zhao J
Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
[TBL] [Abstract][Full Text] [Related]
6. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
[TBL] [Abstract][Full Text] [Related]
7. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
Duo J; Ma Y; Wang G; Han X; Zhang C
DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
Zhou J; Zhang C; Sui X; Cao S; Tang F; Sun S; Wang S; Chen B
Invest New Drugs; 2018 Aug; 36(4):571-580. PubMed ID: 29504068
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
[TBL] [Abstract][Full Text] [Related]
10. The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells.
Liu Z; Jing Q; Wang Y; Li Y; Mi F; Xiang C; Fu R
Int J Mol Med; 2019 Jan; 43(1):285-293. PubMed ID: 30387821
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
He J; Chen Q; Gu H; Chen J; Zhang E; Guo X; Huang X; Yan H; He D; Yang Y; Zhao Y; Wang G; He H; Yi Q; Cai Z
Haematologica; 2018 Aug; 103(8):1369-1379. PubMed ID: 29773595
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Pignochino Y; Grignani G; Cavalloni G; Motta M; Tapparo M; Bruno S; Bottos A; Gammaitoni L; Migliardi G; Camussi G; Alberghini M; Torchio B; Ferrari S; Bussolino F; Fagioli F; Picci P; Aglietta M
Mol Cancer; 2009 Dec; 8():118. PubMed ID: 20003259
[TBL] [Abstract][Full Text] [Related]
14. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma.
Song W; Chen Z; Shi C; Gao Y; Feng X; Li H; Li Z; Zhang M
Hematol Oncol; 2023 Apr; 41(2):257-266. PubMed ID: 34854108
[TBL] [Abstract][Full Text] [Related]
17. Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.
Wang SC; Yu CY; Wu YC; Chang YC; Chen SL; Sung WW
Cancer Lett; 2022 Apr; 530():8-15. PubMed ID: 35033588
[TBL] [Abstract][Full Text] [Related]
18. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
19. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
20. [Effect of chidamide on human B lymphoma cell lines and its mechanisms].
Li YY; Wang YF; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):893-9. PubMed ID: 22931650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]